• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
DXB

DIMERIX LIMITED - Announcements

1.05% ! 47.0¢
Market Cap $282.0M  !

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The... Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. More

Announcements



DXB AGM Presentation30/09/20 download Created with Sketch. 2.33MB
DXB CEO's Address to Shareholders30/09/20 download Created with Sketch. 946.04KB
DXB Virtual Meeting Voting and Registration Guide30/09/20 download Created with Sketch. 447.35KB
DXB Notification of expired Options25/09/20 download Created with Sketch. 349.25KB
DXB Investor Presentation14/09/20 download Created with Sketch. 3.7MB
DXB Positive Top-Line Results in DKD Phase 2 Clinical StudyPRICE SENSITIVE14/09/20 download Created with Sketch. 307.24KB
DXB Trading HaltPRICE SENSITIVE10/09/20 download Created with Sketch. 363.42KB
DXB Dimerix Awarded $1 Million MRFF FundingPRICE SENSITIVE03/09/20 download Created with Sketch. 354.09KB
DXB Notice of Annual General Meeting/Proxy Form01/09/20 download Created with Sketch. 1.09MB
DXB Annual General Meeting - Notice and Letter to Shareholders01/09/20 download Created with Sketch. 818.23KB
DXB Appendix 4G and Corporate Governance Statement27/08/20 download Created with Sketch. 501.91KB
DXB Annual Report to shareholders27/08/20 download Created with Sketch. 3.18MB
DXB Preliminary Final ReportPRICE SENSITIVE27/08/20 download Created with Sketch. 126.66KB
DXB Investor Presentation29/07/20 download Created with Sketch. 3.45MB
DXB Positive Top-Line Results in FSGS Phase 2a Clinical StudyPRICE SENSITIVE29/07/20 download Created with Sketch. 279.06KB
DXB Trading HaltPRICE SENSITIVE27/07/20 download Created with Sketch. 364.82KB
DXB Last Patient Completes Dosing in DKD Phase 2 Clinical StudyPRICE SENSITIVE24/07/20 download Created with Sketch. 245.43KB
DXB Change in substantial holding20/07/20 download Created with Sketch. 444.93KB
DXB Quarterly Appendix 4C and Activities ReportPRICE SENSITIVE14/07/20 download Created with Sketch. 552.22KB
DXB DMX-700 Program for COPD Advances06/07/20 download Created with Sketch. 229.47KB
DXB Cleansing Notice29/06/20 download Created with Sketch. 353.87KB
DXB Appendix 2A29/06/20 download Created with Sketch. 287.2KB
DXB Proposed issue of Securities - DXB22/06/20 download Created with Sketch. 24.96KB
DXB Dimerix Completes $5.8m PlacementPRICE SENSITIVE22/06/20 download Created with Sketch. 258.28KB
DXB Trading HaltPRICE SENSITIVE18/06/20 download Created with Sketch. 553.4KB
DXB Last Patient Completes Dosing in FSGS Phase 2 Clinical StudyPRICE SENSITIVE17/06/20 download Created with Sketch. 261.83KB
DXB Investor Presentation04/06/20 download Created with Sketch. 3.58MB
DXB Global REMAP-CAP Platform Trial Protocol To Include DMX-200PRICE SENSITIVE04/06/20 download Created with Sketch. 287.37KB
DXB Trading HaltPRICE SENSITIVE02/06/20 download Created with Sketch. 363.65KB
DXB Dimerix to Present at NWR Virtual Health Conference01/05/20 download Created with Sketch. 2.49MB
DXB Quarterly Appendix 4C and Activities ReportPRICE SENSITIVE21/04/20 download Created with Sketch. 447.79KB
DXB R&D Tax Incentive FacilityPRICE SENSITIVE03/04/20 download Created with Sketch. 263.77KB
DXB Lapse of Options01/04/20 download Created with Sketch. 259.42KB
DXB Dimerix Clinical Studies Update18/03/20 download Created with Sketch. 515.9KB
DXB Investor Presentation09/03/20 download Created with Sketch. 3.86MB
DXB Dimerix Appoints New DMX-200 Medical Advisory Board06/03/20 download Created with Sketch. 236.41KB
DXB DMX-200 Treatment Continued Under TGA Special Access SchemePRICE SENSITIVE03/03/20 download Created with Sketch. 291.19KB
DXB Half Year Report and Update19/02/20 download Created with Sketch. 268.67KB
DXB Half Yearly Report and AccountsPRICE SENSITIVE19/02/20 download Created with Sketch. 1.19MB
DXB Quarterly Commentary & Appendix 4CPRICE SENSITIVE21/01/20 download Created with Sketch. 512.51KB
DXB Biotech Partnering Showcase Conference Presentation13/01/20 download Created with Sketch. 4.15MB
DXB Change in substantial holding10/01/20 download Created with Sketch. 49.69KB
DXB DMX-200 Clinical Trial UpdatePRICE SENSITIVE07/01/20 download Created with Sketch. 274.26KB
DXB Appendix 3B09/12/19 download Created with Sketch. 508.34KB
DXB Cleansing Notice09/12/19 download Created with Sketch. 353.83KB
DXB Dimerix Completes $2.5m PlacementPRICE SENSITIVE03/12/19 download Created with Sketch. 281.55KB
DXB Trading HaltPRICE SENSITIVE29/11/19 download Created with Sketch. 556.96KB
DXB Results of Meeting28/11/19 download Created with Sketch. 322.37KB
DXB AGM Presentation28/11/19 download Created with Sketch. 1.46MB
DXB CEO's Address to Shareholders28/11/19 download Created with Sketch. 599.69KB
DXB Dimerix Holds Pre-IND Meeting on DMX-200 With FDAPRICE SENSITIVE25/11/19 download Created with Sketch. 227.79KB
DXB Appendix 3B12/11/19 download Created with Sketch. 614.97KB
DXB Bio-Europe Conference Presentation11/11/19 download Created with Sketch. 3.87MB
DXB Ausbiotech Conference Presentation30/10/19 download Created with Sketch. 2.19MB
DXB Notice of Annual General Meeting/Proxy Form29/10/19 download Created with Sketch. 1.24MB
DXB Quarterly Commentary & Appendix 4CPRICE SENSITIVE25/10/19 download Created with Sketch. 565.91KB
DXB Dimerix Awarded Second Innovation Connections Grant23/10/19 download Created with Sketch. 201.82KB
DXB Final Director's Interest Notice11/10/19 download Created with Sketch. 252.26KB
DXB Director Resignation11/10/19 download Created with Sketch. 223.38KB
DXB New Drug Pipeline Candidate DMX-700 & Company UpdatePRICE SENSITIVE10/10/19 download Created with Sketch. 3.08MB
DXB Receipt of R&D Tax IncentivePRICE SENSITIVE08/10/19 download Created with Sketch. 225.43KB
DXB DMX-200 Phase 2 Clinical Study in DKD Completes RecruitmentPRICE SENSITIVE26/09/19 download Created with Sketch. 180.46KB
DXB Additional US Patent Covering DMX-20017/09/19 download Created with Sketch. 187.02KB
DXB Annual Report to shareholders29/08/19 download Created with Sketch. 3.42MB
DXB Appendix 4G and Corporate Governance Statement29/08/19 download Created with Sketch. 388.03KB
DXB Preliminary Final ReportPRICE SENSITIVE29/08/19 download Created with Sketch. 95.58KB
DXB Appendix 3B09/08/19 download Created with Sketch. 458.89KB
DXB Dimerix to Present at Bioshares Biotech Summit 201925/07/19 download Created with Sketch. 977.25KB
DXB Quarterly Commentary & Appendix 4CPRICE SENSITIVE16/07/19 download Created with Sketch. 350.91KB
DXB First DMX-200 Patents To Grant In Europe And Canada11/07/19 download Created with Sketch. 187.22KB
DXB DMX-200 Phase 2 Clinical Trial in FSGS Fully RecruitedPRICE SENSITIVE10/07/19 download Created with Sketch. 231.92KB
DXB Investor Presentation26/06/19 download Created with Sketch. 1.18MB
DXB DMX-200 Clinical UpdatePRICE SENSITIVE26/06/19 download Created with Sketch. 280.1KB
DXB Dimerix Signs Licence Agreement for Receptor-HIT TechnologyPRICE SENSITIVE24/06/19 download Created with Sketch. 195.39KB
DXB DMX-200 Manufacturing UpdatePRICE SENSITIVE27/05/19 download Created with Sketch. 256.75KB
DXB CFO and Company Secretary Appointment/Resignation06/05/19 download Created with Sketch. 400.89KB
DXB Appendix 4C - quarterlyPRICE SENSITIVE26/04/19 download Created with Sketch. 146.02KB
DXB Appendix 3B15/03/19 download Created with Sketch. 420.01KB
DXB Trial Update Presentation05/03/19 download Created with Sketch. 3.21MB
DXB Half Year Report & DMX-200 Clinical Trials Update26/02/19 download Created with Sketch. 192.06KB
DXB Half Yearly Report and AccountsPRICE SENSITIVE26/02/19 download Created with Sketch. 1.22MB
DXB Appendix 4C and Quarterly HighlightsPRICE SENSITIVE31/01/19 download Created with Sketch. 311.52KB
DXB Appendix 3B29/01/19 download Created with Sketch. 421.38KB
DXB Appendix 3B14/01/19 download Created with Sketch. 422.53KB
DXB Dimerix Receives R&D Tax Cash Rebate Totalling $1.07mPRICE SENSITIVE20/12/18 download Created with Sketch. 124.97KB
DXB Change of Director's Interest Notice27/11/18 download Created with Sketch. 203.71KB
DXB Appendix 3B27/11/18 download Created with Sketch. 431.66KB
DXB Dimerix Awarded $50,000 Innovation Connections Grant26/11/18 download Created with Sketch. 145.77KB
DXB 1st Patient Dosed in DMX-200 Clinical Trial for FSGSPRICE SENSITIVE22/11/18 download Created with Sketch. 133.95KB
DXB DXB Receives Orphan Drug Designation in EUPRICE SENSITIVE21/11/18 download Created with Sketch. 186.18KB
DXB FIRST PATIENT DOSED IN DMX-200 CLINICAL TRIALPRICE SENSITIVE19/11/18 download Created with Sketch. 132.96KB
DXB Change of Address12/11/18 download Created with Sketch. 117.14KB
DXB Results of Meeting30/10/18 download Created with Sketch. 141.49KB
DXB AGM Presentation and CEO Address30/10/18 download Created with Sketch. 1.61MB
DXB Appendix 4C - quarterlyPRICE SENSITIVE29/10/18 download Created with Sketch. 148.78KB
DXB AGM Dial-In Details25/10/18 download Created with Sketch. 73.92KB
DXB Investor Update15/10/18 download Created with Sketch. 1.72MB
DXB Appendix 3B24/09/18 download Created with Sketch. 443.6KB
DXB Notice of Annual General Meeting/Proxy Form21/09/18 download Created with Sketch. 754.2KB
DXB Change of Director's Interest Notice11/09/18 download Created with Sketch. 200.78KB
DXB AGM Presentation
30/09/20 download Created with Sketch. 2.33MB
DXB CEO's Address to Shareholders
30/09/20 download Created with Sketch. 946.04KB
DXB Virtual Meeting Voting and Registration Guide
30/09/20 download Created with Sketch. 447.35KB
DXB Notification of expired Options
25/09/20 download Created with Sketch. 349.25KB
DXB Investor Presentation
14/09/20 download Created with Sketch. 3.7MB
DXB Positive Top-Line Results in DKD Phase 2 Clinical Study
14/09/20PRICE SENSITIVE download Created with Sketch. 307.24KB
DXB Trading Halt
10/09/20PRICE SENSITIVE download Created with Sketch. 363.42KB
DXB Dimerix Awarded $1 Million MRFF Funding
03/09/20PRICE SENSITIVE download Created with Sketch. 354.09KB
DXB Notice of Annual General Meeting/Proxy Form
01/09/20 download Created with Sketch. 1.09MB
DXB Annual General Meeting - Notice and Letter to Shareholders
01/09/20 download Created with Sketch. 818.23KB
DXB Appendix 4G and Corporate Governance Statement
27/08/20 download Created with Sketch. 501.91KB
DXB Annual Report to shareholders
27/08/20 download Created with Sketch. 3.18MB
DXB Preliminary Final Report
27/08/20PRICE SENSITIVE download Created with Sketch. 126.66KB
DXB Investor Presentation
29/07/20 download Created with Sketch. 3.45MB
DXB Positive Top-Line Results in FSGS Phase 2a Clinical Study
29/07/20PRICE SENSITIVE download Created with Sketch. 279.06KB
DXB Trading Halt
27/07/20PRICE SENSITIVE download Created with Sketch. 364.82KB
DXB Last Patient Completes Dosing in DKD Phase 2 Clinical Study
24/07/20PRICE SENSITIVE download Created with Sketch. 245.43KB
DXB Change in substantial holding
20/07/20 download Created with Sketch. 444.93KB
DXB Quarterly Appendix 4C and Activities Report
14/07/20PRICE SENSITIVE download Created with Sketch. 552.22KB
DXB DMX-700 Program for COPD Advances
06/07/20 download Created with Sketch. 229.47KB
DXB Cleansing Notice
29/06/20 download Created with Sketch. 353.87KB
DXB Appendix 2A
29/06/20 download Created with Sketch. 287.2KB
DXB Proposed issue of Securities - DXB
22/06/20 download Created with Sketch. 24.96KB
DXB Dimerix Completes $5.8m Placement
22/06/20PRICE SENSITIVE download Created with Sketch. 258.28KB
DXB Trading Halt
18/06/20PRICE SENSITIVE download Created with Sketch. 553.4KB
DXB Last Patient Completes Dosing in FSGS Phase 2 Clinical Study
17/06/20PRICE SENSITIVE download Created with Sketch. 261.83KB
DXB Investor Presentation
04/06/20 download Created with Sketch. 3.58MB
DXB Global REMAP-CAP Platform Trial Protocol To Include DMX-200
04/06/20PRICE SENSITIVE download Created with Sketch. 287.37KB
DXB Trading Halt
02/06/20PRICE SENSITIVE download Created with Sketch. 363.65KB
DXB Dimerix to Present at NWR Virtual Health Conference
01/05/20 download Created with Sketch. 2.49MB
DXB Quarterly Appendix 4C and Activities Report
21/04/20PRICE SENSITIVE download Created with Sketch. 447.79KB
DXB R&D Tax Incentive Facility
03/04/20PRICE SENSITIVE download Created with Sketch. 263.77KB
DXB Lapse of Options
01/04/20 download Created with Sketch. 259.42KB
DXB Dimerix Clinical Studies Update
18/03/20 download Created with Sketch. 515.9KB
DXB Investor Presentation
09/03/20 download Created with Sketch. 3.86MB
DXB Dimerix Appoints New DMX-200 Medical Advisory Board
06/03/20 download Created with Sketch. 236.41KB
DXB DMX-200 Treatment Continued Under TGA Special Access Scheme
03/03/20PRICE SENSITIVE download Created with Sketch. 291.19KB
DXB Half Year Report and Update
19/02/20 download Created with Sketch. 268.67KB
DXB Half Yearly Report and Accounts
19/02/20PRICE SENSITIVE download Created with Sketch. 1.19MB
DXB Quarterly Commentary & Appendix 4C
21/01/20PRICE SENSITIVE download Created with Sketch. 512.51KB
DXB Biotech Partnering Showcase Conference Presentation
13/01/20 download Created with Sketch. 4.15MB
DXB Change in substantial holding
10/01/20 download Created with Sketch. 49.69KB
DXB DMX-200 Clinical Trial Update
07/01/20PRICE SENSITIVE download Created with Sketch. 274.26KB
DXB Appendix 3B
09/12/19 download Created with Sketch. 508.34KB
DXB Cleansing Notice
09/12/19 download Created with Sketch. 353.83KB
DXB Dimerix Completes $2.5m Placement
03/12/19PRICE SENSITIVE download Created with Sketch. 281.55KB
DXB Trading Halt
29/11/19PRICE SENSITIVE download Created with Sketch. 556.96KB
DXB Results of Meeting
28/11/19 download Created with Sketch. 322.37KB
DXB AGM Presentation
28/11/19 download Created with Sketch. 1.46MB
DXB CEO's Address to Shareholders
28/11/19 download Created with Sketch. 599.69KB
DXB Dimerix Holds Pre-IND Meeting on DMX-200 With FDA
25/11/19PRICE SENSITIVE download Created with Sketch. 227.79KB
DXB Appendix 3B
12/11/19 download Created with Sketch. 614.97KB
DXB Bio-Europe Conference Presentation
11/11/19 download Created with Sketch. 3.87MB
DXB Ausbiotech Conference Presentation
30/10/19 download Created with Sketch. 2.19MB
DXB Notice of Annual General Meeting/Proxy Form
29/10/19 download Created with Sketch. 1.24MB
DXB Quarterly Commentary & Appendix 4C
25/10/19PRICE SENSITIVE download Created with Sketch. 565.91KB
DXB Dimerix Awarded Second Innovation Connections Grant
23/10/19 download Created with Sketch. 201.82KB
DXB Final Director's Interest Notice
11/10/19 download Created with Sketch. 252.26KB
DXB Director Resignation
11/10/19 download Created with Sketch. 223.38KB
DXB New Drug Pipeline Candidate DMX-700 & Company Update
10/10/19PRICE SENSITIVE download Created with Sketch. 3.08MB
DXB Receipt of R&D Tax Incentive
08/10/19PRICE SENSITIVE download Created with Sketch. 225.43KB
DXB DMX-200 Phase 2 Clinical Study in DKD Completes Recruitment
26/09/19PRICE SENSITIVE download Created with Sketch. 180.46KB
DXB Additional US Patent Covering DMX-200
17/09/19 download Created with Sketch. 187.02KB
DXB Annual Report to shareholders
29/08/19 download Created with Sketch. 3.42MB
DXB Appendix 4G and Corporate Governance Statement
29/08/19 download Created with Sketch. 388.03KB
DXB Preliminary Final Report
29/08/19PRICE SENSITIVE download Created with Sketch. 95.58KB
DXB Appendix 3B
09/08/19 download Created with Sketch. 458.89KB
DXB Dimerix to Present at Bioshares Biotech Summit 2019
25/07/19 download Created with Sketch. 977.25KB
DXB Quarterly Commentary & Appendix 4C
16/07/19PRICE SENSITIVE download Created with Sketch. 350.91KB
DXB First DMX-200 Patents To Grant In Europe And Canada
11/07/19 download Created with Sketch. 187.22KB
DXB DMX-200 Phase 2 Clinical Trial in FSGS Fully Recruited
10/07/19PRICE SENSITIVE download Created with Sketch. 231.92KB
DXB Investor Presentation
26/06/19 download Created with Sketch. 1.18MB
DXB DMX-200 Clinical Update
26/06/19PRICE SENSITIVE download Created with Sketch. 280.1KB
DXB Dimerix Signs Licence Agreement for Receptor-HIT Technology
24/06/19PRICE SENSITIVE download Created with Sketch. 195.39KB
DXB DMX-200 Manufacturing Update
27/05/19PRICE SENSITIVE download Created with Sketch. 256.75KB
DXB CFO and Company Secretary Appointment/Resignation
06/05/19 download Created with Sketch. 400.89KB
DXB Appendix 4C - quarterly
26/04/19PRICE SENSITIVE download Created with Sketch. 146.02KB
DXB Appendix 3B
15/03/19 download Created with Sketch. 420.01KB
DXB Trial Update Presentation
05/03/19 download Created with Sketch. 3.21MB
DXB Half Year Report & DMX-200 Clinical Trials Update
26/02/19 download Created with Sketch. 192.06KB
DXB Half Yearly Report and Accounts
26/02/19PRICE SENSITIVE download Created with Sketch. 1.22MB
DXB Appendix 4C and Quarterly Highlights
31/01/19PRICE SENSITIVE download Created with Sketch. 311.52KB
DXB Appendix 3B
29/01/19 download Created with Sketch. 421.38KB
DXB Appendix 3B
14/01/19 download Created with Sketch. 422.53KB
DXB Dimerix Receives R&D Tax Cash Rebate Totalling $1.07m
20/12/18PRICE SENSITIVE download Created with Sketch. 124.97KB
DXB Change of Director's Interest Notice
27/11/18 download Created with Sketch. 203.71KB
DXB Appendix 3B
27/11/18 download Created with Sketch. 431.66KB
DXB Dimerix Awarded $50,000 Innovation Connections Grant
26/11/18 download Created with Sketch. 145.77KB
DXB 1st Patient Dosed in DMX-200 Clinical Trial for FSGS
22/11/18PRICE SENSITIVE download Created with Sketch. 133.95KB
DXB DXB Receives Orphan Drug Designation in EU
21/11/18PRICE SENSITIVE download Created with Sketch. 186.18KB
DXB FIRST PATIENT DOSED IN DMX-200 CLINICAL TRIAL
19/11/18PRICE SENSITIVE download Created with Sketch. 132.96KB
DXB Change of Address
12/11/18 download Created with Sketch. 117.14KB
DXB Results of Meeting
30/10/18 download Created with Sketch. 141.49KB
DXB AGM Presentation and CEO Address
30/10/18 download Created with Sketch. 1.61MB
DXB Appendix 4C - quarterly
29/10/18PRICE SENSITIVE download Created with Sketch. 148.78KB
DXB AGM Dial-In Details
25/10/18 download Created with Sketch. 73.92KB
DXB Investor Update
15/10/18 download Created with Sketch. 1.72MB
DXB Appendix 3B
24/09/18 download Created with Sketch. 443.6KB
DXB Notice of Annual General Meeting/Proxy Form
21/09/18 download Created with Sketch. 754.2KB
DXB Change of Director's Interest Notice
11/09/18 download Created with Sketch. 200.78KB
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
47.0¢
Change
-0.005(1.05%)
Mkt cap ! $282.0M
Open High Low Value Volume
47.0¢ 49.3¢ 46.5¢ $1.188M 2.509M

Buyers (Bids)

No. Vol. Price($)
3 28330 47.0¢
 

Sellers (Offers)

Price($) Vol. No.
49.0¢ 48233 4
View Market Depth
Last trade - 16.10pm 31/07/2025 (20 minute delay) ?
Last
47.0¢
  Change
-0.005 ( 1.67 %)
Open High Low Volume
47.0¢ 48.5¢ 46.5¢ 960457
Last updated 15.55pm 31/07/2025 ?
DXB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.